What kind of vaccine is Sputnik V, how does it work, and what data are we missing?
Academic rigour, journalistic flair
Articles on Clinical trials
Displaying 1 - 20 of 162 articles
Investigations have led to the withdrawal of a study backing ivermectin to treat COVID-19. But that’s not the last time we’ll hear about this controversial drug.
Exclusion from clinical trials, lack of data and inconsistent information made it difficult for pregnant and breastfeeding people to make decisions about COVID-19 vaccines early in the rollout.
Ongoing tracking is meant to spot very rare risks – like the connection between the Johnson & Johnson shot and Guillain-Barré syndrome. And it relies on public reporting.
As many teens and adults in the US restart their social lives, parents of children under the age of 12 wonder when their kids will also be able to experience the freedom that comes with vaccination.
Relying on donor funding means that the funder ultimately determines the health priorities. This is one reason why many programmes in Africa focus on a single disease such as HIV.
A new network of public clinical trials institutes is urgently needed to replenish the empty pipeline for new antibiotics.
While it’s potentially promising, there’s not enough information yet to determine if the vaccine is safe and effective.
Even if we came up with a definition of what makes the “best” vaccine, we don’t have the luxury of choice, when vaccines are in short supply.
The new drug is based on the idea that a build-up of amyloid in the brain leads to the disease. But that hypothesis has been under scrutiny lately.
The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
It sounds too good to be true, a vaccine that can protect against future virus variants. But governments around the world are keen to learn more.
With four COVID-19 vaccines approved for use in Canada, it’s time to answer FAQs about efficacy, immunity, eradication and variants.
A whistle-stop tour of the history of placebos.
We still don’t know if current vaccines prevent people from transmitting the virus to others. Here’s why that matters in 2021.
The reason the vaccine appears to have worked better in participants who initially received only half a dose is still somewhat of a mystery.
Vaccines are being touted as taking seven to ten years to develop. But you shouldn’t be worried that COVID vaccines only took less than a year.
COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.
Early data shows that vaccines work for older people who are more at risk of severe COVID-19.
Asking these four questions can help us identify good news when we see it, be more critical of news reports, or delay our judgement until we have more information.
Top contributors
-
Associate Professor of the Sydney Pharmacy School, University of Sydney
-
Director of the Oxford Empathy Programme, University of Oxford
-
Epidemiologist, Cochrane
-
Professor Emeritus of Health Policy and Management, York University, Emergency Physician at University Health Network, Associate Professor of Family and Community Medicine, University of Toronto
-
Professor of Immunology, RMIT University
-
Professor of Medicine, Monash University
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Senior Research Fellow, Bioethics, University of Sydney
-
Adjunct Clinical Associate Professor, AMREP Department of Medicine, Alfred Hospital, Melbourne & Senior Medical Oncologist and Palliative Care Physician, Melbourne Oncology Group, Cabrini Haematology and Oncology Centre, Wattletree Road, Malvern, Monash University
-
Head, Cancer Research Program, Monash University
-
Senior Lecturer in Medical Ethics and Law, St George's, University of London
-
Researcher, L’Université d’Ottawa/University of Ottawa
-
Professsor of Public Health; Co-Director Consortium for Advanced Research Training in Africa; Panel Member, Private Healthcare Market Inquiry, University of the Witwatersrand
-
Head of School and Dean of Pharmacy, University of Sydney
-
Assistant Professor of Law, Saint Louis University
